Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

CGTLive Interview: New Frontiers in Allogeneic Cell Therapy

By Karen Loudon / January 20, 2023
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and...
Read More

Cartherics granted first patent in China for multiple development candidates

By Karen Loudon / January 9, 2023
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment...
Read More

Cartherics to Present at Biotech Showcase™ 2023

By Karen Loudon / December 22, 2022
Cartherics to Present at Biotech Showcase™ 2023 Dr Ian Nisbet will provide a presentation on Cartherics’ technology and development program...
Read More